| | | | |

What Type of Mesothelioma Do I Have? CT May Be Able to Tell

Researchers from one of the country’s top cancer centers say it may be possible to tell what subtype of pleural mesothelioma a person has by using computed tomography (CT).

Pleural mesothelioma is an aggressive lung-related cancer for which patients and their doctors must develop a treatment plan quickly to get ahead of the disease. The challenge is that, not only is mesothelioma highly resistant to standard cancer treatment, but different subtypes of mesothelioma are often managed with different drugs and therapies.

The new study from Memorial Sloan Kettering Cancer Center in New York suggests that CT may offer an accurate and non-invasive way to classify mesothelioma patients which could speed the treatment planning process and lead to longer mesothelioma survival.

Computed Tomography for Mesothelioma Diagnosis

The new study focuses on computed tomography or CT,  an imaging tool that compiles a series of X-ray images into a three dimensional model of the inside of the body.

People with suspected malignant mesothelioma are often recommended for a CT scan so that doctors can see if there are masses, excess fluid, or calcified areas in their chest that could indicate cancer.

To improve the accuracy of a CT scan, it may be combined with a contrast material, a dye that temporarily changes the way certain types of tissues appear on X-rays. In combination with contrast materials, CT scans can help doctors determine if mesothelioma cells have spread to lymph nodes, nearby tissues or other organs.

Identifying Mesothelioma Subtypes with CT

The new CT study of mesothelioma subtypes included 125 patients with malignant pleural mesothelioma.

Ninety-seven of the patients (77%) had the epithelioid mesothelioma subtype, the type of mesothelioma that this not only most common but also most receptive to treatment. Seventeen patients (14%) had the biphasic mesothelioma subtype and 11 (9%) had the sarcomatoid mesothelioma.

Most of the patients in the study had a common symptom of mesothelioma called pleural plaques, non-cancerous thickened, fibrous areas on the the pleural lining around the lungs.

Most of the time, pleural plaques are not calcified, meaning they have not been hardened by deposits of soluble calcium. But the study found that people who had either one of the non-epithelioid subtypes of pleural mesothelioma were much more likely to have calcified pleural plaques.

“Calcified plaques are significantly more common in non-epithelioid subtypes compared with epithelioid malignant pleural mesothelioma,” writes radiologist Joanna Escalon, MD, in the Journal of Computer Assisted Tomography. “Given the different prognoses and management of malignant pleural mesothelioma subtypes, accurate noninvasive subtype classification is clinically vital.”

CT is now being used in some places to screen heavy smokers for early signs of lung cancer and it has been suggested that it might also be useful for screening asbestos-exposed people in order to diagnose mesothelioma earlier.

Source:

Escalon, JG, et al, “Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?”, April 2, 2018, Journal of Computer Assisted Tomography, Epub ahead of print

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • |

    Mesothelioma Case Shows Danger of Accidental Asbestos Exposure

    A mesothelioma case in Birmingham, England is a dramatic illustration of the very real danger of hidden asbestos. The widow of a physician who died of mesothelioma last year at the age of 51 claims her husband was exposed to asbestos just walking to and from his medical classes. Monisha Coelho believes that exposed asbestos insulation in the underground hallways that connect the University of Birmingham to buildings on the Queen Elizabeth Hospital campus triggered Dr. Ian Pardoe’s mesothelioma. In an article in the Birmingham Mail, Coelho explained how her husband decided how and where the deadly exposure had occurred. “Ian thought long and hard about where he might have come into contact with asbestos,” Coelho told the paper. “He…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…